Canada Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Canada Pharmaceutical Market is segmented by ATC/Therapeutic Class, Drug Type, and Prescription Type

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
CAGR: 2.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Canada Pharmaceutical market studied was anticipated to show a slow growth with a CAGR of 2.4%. The pharmaceutical industry is one of Canada's key creative sectors. It is comprised of businesses producing and developing new drugs and generic drugs, and also over the counter pharmaceuticals. The sector is made up of a variety of sub-sectors that represent specific consumer segments. That includes brand-name drug firms, generic pharmaceutical companies, pharmaceutical medium and small-sized businesses (pharmaceutical SMEs), contract manufacturing organizations (CRO-CMOs), and contract research organizations (CROs).

The nation's pharmaceutical sector is moving towards externalized R&D through alliances and associations, with the government imposing up initiatives such as the Business-led Networks of Centers of Excellence (BL-NCEs), the Centers of Excellence for Commercialization of Research (CECR) and other research projects such as the Structural Genomics Consortium. Greater investment by multinational pharmaceutical and biotech firms in academic translational industrial operations has played an important role in driving the country's growth. However, clinical trials undertaken by pharmaceutical firms and growth in the geriatric population are further driving market growth in the country during the forecast period.

Scope of the Report

As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption to treat various illnesses. The report also covers an in-depth analysis of qualitative and quantitative data.

By ATC/Therapeutic Class
Alimentary Tract and Metabolism
Blood and Blood Forming Organs
Cardiovascular System
Genito Urinary System and Sex Hormones
Systemic Hormonal Preparations,
Antiinfectives For Systemic Use
Antineoplastic and Immunomodulating Agents
Musculo-Skeletal System
Nervous System
Antiparasitic Products, Insecticides and Repellents
Respiratory System
Sensory Organs
By Drug Type
By Prescription Type
Prescription Drugs (Rx)
OTC Drugs

Report scope can be customized per your requirements. Click here.

Key Market Trends

Healthcare Expenditure in Canada

Canada has a healthcare program that is funded by taxes and public financing. As of 2019, overall healthcare spending in Canada is estimated to be $264 billion, or $7,068 per capita. overall, healthcare expenditure is expected to constitute 11.6 percent of Canada's GDP, an improvement from the preceding years, and a substantial rise from the 1970s, just prior to the introduction of the 1984 Canadian Health Act. Healthcare expenditure is the largest among seniors citizens. While per-capita spending rose dramatically from $6,656 for those aged 65-69 to $20,793 for those aged 80 and over, aging is a moderate cause of increasing health care expenses, at around 1% a year in Canada. The public sector accounts for the vast majority of healthcare expenditures in the public and private sectors of Canada's healthcare system. Regional governments are liable for much of the financing for health services, followed by additional government funds. Nevertheless, pharmaceutical spending is generally funded by government sector capital.


Prescription Drugs segment Holds the Largest Share and is Expected to do Same in the Forecast Period

The Canadian Prescription Drugs category is expected to reflect the largest proportion in the predicted period. Market drivers for this sector are technical advances, a conducive governmental landscape, the preference of pharmaceutical companies for prescription drugs, and new product launches are also responsible for this positive trend. It would also be attributed to a rise in population growth and a rise in chronic diseases such as cancer, autoimmune diseases, cardiovascular disease in the country, along with a rise in per capita healthcare expenditure in the country and a change in people's disposable income that will drive growth during the forecast era.

Cancer cases canada.png

Competitive Landscape

The Canadian pharmaceutical market is highly competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions in the country. Some of the Key companies which are currently dominating the market are Johnson & Johnson, Novartis International AG, Merck & Co., Inc., Pfizer Inc., and Bayer AG

Table of Contents


    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure (Govt. Vs Private)

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemiology Data For key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)

      6. 4.1.6 Pipeline Analysis

        1. By Phase

        2. By Sponsor

        3. By Disease

      7. 4.1.7 Statistical Overview

        1. Number of Hospitals

        2. Employment in the Pharmaceutical Sector

        3. R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Rising geriatric Population

      2. 4.2.2 Rising Incidence of Chronic Disease

    3. 4.3 Market Restraints

      1. 4.3.1 Highly Expensive Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By ATC/Therapeutic Class

      1. 5.1.1 Alimentary Tract and Metabolism

      2. 5.1.2 Blood and Blood Forming Organs

      3. 5.1.3 Cardiovascular System

      4. 5.1.4 Dermatologicals

      5. 5.1.5 Genito Urinary System and Sex Hormones

      6. 5.1.6 Systemic Hormonal Preparations,

      7. 5.1.7 Antiinfectives For Systemic Use

      8. 5.1.8 Antineoplastic and Immunomodulating Agents

      9. 5.1.9 Musculo-Skeletal System

      10. 5.1.10 Nervous System

      11. 5.1.11 Antiparasitic Products, Insecticides and Repellents

      12. 5.1.12 Respiratory System

      13. 5.1.13 Sensory Organs

      14. 5.1.14 Various

    2. 5.2 By Drug Type

      1. 5.2.1 Branded

      2. 5.2.2 Generic

    3. 5.3 By Prescription Type

      1. 5.3.1 Prescription Drugs (Rx)

      2. 5.3.2 OTC Drugs


    1. 6.1 Company Profile

      1. 6.1.1 Johnson & Johnson

      2. 6.1.2 Novartis International AG

      3. 6.1.3 Bayer AG

      4. 6.1.4 Merck & Co., Inc.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 F. Hoffmann-La Roche AG

      7. 6.1.7 Bristol Myers Squibb Company

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 AbbVie Inc.

      10. 6.1.10 Sanofi S.A.



**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Canada Pharmaceutical Market market is studied from 2018 - 2026.

The Canada Pharmaceutical Market is growing at a CAGR of 2.4% over the next 5 years.

Johnson & Johnson, Novartis International AG, Merck & Co., Inc., Pfizer Inc., Bayer AG are the major companies operating in Canada Pharmaceutical Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!